Official Title

Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Intervention/Treatment

    kefir ...
  • Study Participants

    125
The purpose of this study is to determine the effectiveness of commercially available kefir on preventing antibiotic-associated diarrhea compared to placebo in children ages 1-5.
Diarrhea is a common and costly disease of children in the United States. Children less than 5 years of age experience 20-35 million episodes of diarrhea per year. These episodes lead to 2-3.5 million physician visits (which account for 10% of all visits), more than 200,000 hospitalizations (13% of hospital admissions in children less than 5 years), and 325-425 deaths annually. In 1991, the outpatient costs of treating diarrhea for children under age 3 were calculated at 0.6-1 billion dollars per year.

Acute diarrhea in young children is almost always caused by infections or antibiotics. The rate of diarrhea associated with antibiotic usage is 20-35%, with children 3-36 months receiving on average 2-3 antibiotic prescriptions per year. Studies have shown that diarrhea due to either antibiotics or infections is caused by disturbances of the microflora of the gastrointestinal tract.

The current treatment for diarrhea in young children is oral rehydration, which is used to treat dehydration but plays no role in prevention. Probiotics are live microorganisms which, when administered in sufficient amounts, may improve health. Probiotics have the potential to treat and prevent diarrhea by improving the intestinal flora when disturbed by events such as antibiotics. Important to their use is that they are of human origin, survive passage through the gut, and are safe in very large dosages.

Studies have examined the potential health benefits of probiotics in the prevention and treatment of both antibiotic and infectious diarrhea. The probiotics have generally been given as supplements or pills. In placebo controlled randomized studies using these techniques, probiotics have generally been shown to decrease antibiotic associated diarrhea by 15-25% over placebo. Other studies have enrolled children with acute diarrhea, generally from rotavirus, and found a 30-50% cure rate in the probiotic group over placebo.

Kefir, available in the United States, is a milk product derived by the action of ten probiotics. A daily dose of 10^6-10^9 colony forming units of probiotics has been studied and recommended for health benefits.
Study Started
Jul 31
2007
Primary Completion
Apr 30
2008
Study Completion
Apr 30
2008
Results Posted
Mar 26
2012
Estimate
Last Update
Jul 10
2019

Other Kefir

The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.

Other Placebo

The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.

Placebo Placebo Comparator

Kefir Experimental

Criteria

Inclusion Criteria:

Ability to speak and write English
Aged 1-5 years
Male or female
Diagnosed with an upper respiratory infection and placed on a penicillin class antibiotic regimen for 10 days

Exclusion Criteria:

Developmental delays
Chronic conditions, such as diabetes or asthma, that require medication
Prematurity, birth weight <2500 grams
Allergy to kefir and/or milk
Active diarrhea
Congenital anomalies
Failure to thrive
Parental belief of lactose intolerance

Summary

Placebo

Kefir

All Events

Event Type Organ System Event Term Placebo Kefir

Incidence of Participants With Diarrhea by Parental Report

The primary outcome was the incidence of participants receiving antibiotics with diarrhea during the 14-day follow-up period, as determined by parental report.

Kefir

18.0
Percentage of participants
95% Confidence Interval: 9.0 to 30.0

Placebo

21.9
Percentage of participants
95% Confidence Interval: 13.0 to 24.0

Incidence of Vomiting, Stomach Pain, Constipation, Runny Nose, Cough, Earaches, Fever, Irritability, Lethargy, and Loose Stools

Incidence of Vomiting, Stomach Pain, Constipation, Runny Nose, Cough, Earaches, Fever, Irritability, Lethargy, and Loose Stools. Outcomes assessed by parental report via daily diary and phone follow-ups with study research assistants on days 0, 5, 10, and 15.

Kefir

constipation

19.7
Percentage of participants
95% Confidence Interval: 11.0 to 32.0

cough

68.9
Percentage of participants
95% Confidence Interval: 56.0 to 80.0

earaches

23.0
Percentage of participants
95% Confidence Interval: 13.0 to 36.0

fever

45.9
Percentage of participants
95% Confidence Interval: 33.0 to 59.0

irritability

19.7
Percentage of participants
95% Confidence Interval: 11.0 to 32.0

lethargy

16.4
Percentage of participants
95% Confidence Interval: 8.0 to 28.0

loose stools

29.5
Percentage of participants
95% Confidence Interval: 19.0 to 43.0

runny nose

77.0
Percentage of participants
95% Confidence Interval: 65.0 to 87.0

stomach pain

8.2
Percentage of participants
95% Confidence Interval: 3.0 to 18.0

vomiting

16.4
Percentage of participants
95% Confidence Interval: 8.0 to 28.0

Placebo

constipation

17.2
Percentage of participants
95% Confidence Interval: 9.0 to 29.0

cough

53.1
Percentage of participants
95% Confidence Interval: 40.0 to 66.0

earaches

17.2
Percentage of participants
95% Confidence Interval: 9.0 to 29.0

fever

39.1
Percentage of participants
95% Confidence Interval: 27.0 to 52.0

irritability

18.8
Percentage of participants
95% Confidence Interval: 10.0 to 31.0

lethargy

21.9
Percentage of participants
95% Confidence Interval: 13.0 to 46.0

loose stools

32.8
Percentage of participants
95% Confidence Interval: 22.0 to 46.0

runny nose

82.8
Percentage of participants
95% Confidence Interval: 71.0 to 91.0

stomach pain

14.1
Percentage of participants
95% Confidence Interval: 7.0 to 25.0

vomiting

10.9
Percentage of participants
95% Confidence Interval: 5.0 to 21.0

Total

125
Participants

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Placebo

Kefir